Biochemical and ultrastructural integrity of the saphenous vein conduit during coronary artery bypass grafting. Preliminary results of the effect of papaverine.
Factors associated with early and late graft patency related to aorta-coronary artery bypass grafting with a reversed segment of saphenous vein are clinically important. The present investigation examines the biochemical and electron microscopic integrity of this venous conduit intraoperatively with regard to pharmacologic manipulation with papaverine. Portions of saphenous vein were analyzed in 22 patients undergoing coronary artery bypass operations. Levels of a stable derivative of prostacyclin, 6-keto-PGF1 alpha, were measured by radioimmunoassay. Scanning as well as transmission electron microscopy was also performed. In particular, the efficacy of local vein treatment with papaverine, a phosphodiesterase inhibitor, was evaluated. We found that levels of 6-keto-PGF1 alpha in venous effluent showed a biphasic response with initial elevation followed by a relative depression after papaverine exposure. There were no such changes observed in veins subjected to a balanced electrolyte solution (Plasma-Lyte). In addition, levels of the platelet-inhibitory substance 6-keto-PGF1 alpha in venous tissue were less in papaverine-treated veins than those found in veins treated only with the balanced electrolyte solution (Plasma-Lyte). Furthermore, evidence for ultrastructural damage was also somewhat greater in the papaverine-treated group. An alternative method of dilating the saphenous vein after harvesting, which involves the creation of the proximal aorta-coronary anastomosis first and gentle finger manipulation subsequently, appeared to minimize venous injury. Under present clinical conditions, it appears that some amount of injury is inevitable during harvesting and suturing of the human saphenous vein during coronary bypass grafting.
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis; D001026:Coronary Artery Bypass; D004341:Drug Evaluation; D011464:Epoprostenol / Q000096:biosynthesis; D005942:Gluconates; D006801:Humans; D066298:In Vitro Techniques; D007430:Intraoperative Care; D007552:Isotonic Solutions / Q000494:pharmacology; D015636:Magnesium Chloride; D008855:Microscopy, Electron, Scanning; D010208:Papaverine / Q000494:pharmacology*; D011189:Potassium Chloride; D012501:Saphenous Vein / Q000187:drug effects / Q000637:transplantation / Q000648:ultrastructure*; D019346:Sodium Acetate; D012965:Sodium Chloride; D013997:Time Factors
D005942:Gluconates; D007552:Isotonic Solutions; C012499:Plasma-lyte 148; D015636:Magnesium Chloride; D012965:Sodium Chloride; D019346:Sodium Acetate; D015121:6-Ketoprostaglandin F1 alpha; D011189:Potassium Chloride; D010208:Papaverine; D011464:Epoprostenol